Micrazim capsules 25000 IU 20 pcs
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Pancreatin
Release form
Capsules
Composition
Active ingredient: Pancreatin (Pancreatin) Active ingredient concentration (mg): 128
Pharmacological effect
Enzyme agent. Contains pancreatic enzymes - amylase, lipase and proteases, which facilitate the digestion of carbohydrates, fats and proteins, which contributes to their more complete absorption in the small intestine. In diseases of the pancreas, it compensates for the insufficiency of its exocrine function and contributes to the improvement of the digestive process.
Pharmacokinetics
The pharmacokinetics of pancreatin has not been studied.
Indications
For replacement therapy in pancreatic enzyme insufficiency, associated with: hereditary diseases - cystic fibrosis (pancreatic fibrosis), chronic pancreatitis, pancreatic tumors, pancreatic surgery. The replacement therapy for pancreatic enzyme insufficiency cannot replace the treatment of the underlying disease. therapy in complex treatment for the correction of digestive disorders arising from other diseases and and pathological conditions of the gastrointestinal tract: conditions after resection of the stomach, gall bladder, part of the intestine, diseases and conditions involving a violation of the biliary process (liver disease, cholecystitis, gall bladder stones, chronic diseases of the biliary tract, compression of the biliary tract by new growths, cystic growths and others; diseases of the small intestine and duodenum, large intestine, accompanied by a violation of the promotion of intestinal contents. For learning the process of digesting food in adults and children with normal gastrointestinal function in the case of: errors in the diet (eating fatty and coarse food, overeating, irregular nutrition); for violations of the chewing function, sedentary lifestyle, prolonged immobilization. For use in comprehensive preparation for X-ray examination and ultrasound of the abdominal organs.
Contraindications
Individual intolerance to pancreatin or individual components of the drug.
Precautionary measures
Do not exceed recommended doses.
Use during pregnancy and lactation
The safety of using pancreatin during pregnancy has not been studied enough. Use is possible in cases where the expected benefit to the mother outweighs the potential risk to the fetus. In experimental studies, it was found that pancreatin does not have a teratogenic effect.
Dosage and administration
The dose of the drug is selected individually depending on the age, degree of symptoms and composition of the diet. Dose selection is carried out with the help of registered medicinal products Micrasim 10 000 IU and Micrazim 25 000 IU. Capsules are ingested, squeezed with a sufficient amount of non-alkaline liquid (water, fruit juices). If a single dose of the drug is more than 1 capsule, you should take half of the total number of capsules immediately before a meal, and the other half - while eating. If a single dose is 1 capsule, it should be taken with food. When swallowing is difficult (for example, in young children or the elderly), the capsule can be opened and taken directly in microgranules, pre-mixed with liquid or liquid food (pH <5, 0), does not require chewing (applesauce, yogurt). The grinding or chewing of microgranules, as well as adding them to food with a pH above 5.5, leads to the destruction of their shell, which protects against the action of gastric juice. Any mixture of microgranules with food or liquid should be taken immediately after preparation. The permissible dose for children under the age of 1.5 years - 50 000 IU / day; over 1.5 years old - 100,000 U / day. The duration of receiving pancreatin can vary from several days (digestive disorders) to several months or years (long-term replacement therapy). Substitution therapy for various types of exocrine pancreatic insufficiency. The dose is chosen individually and depends on the severity of exocrine insufficiency, individual eating habits and the age of the patient . Steatorrhea (more than 15 g of fat in the feces per day). In the presence of diarrhea, weight loss and no effect on diet therapy prescribed t 25 000 units of lipase at each meal. If necessary and well tolerated, the dose is increased to 30,000 - 35,000 IU of lipase per dose. A further increase in the dose, in most cases, does not improve the results of treatment and requires a review of the diagnosis, a decrease in the fat content in the diet, and / or an additional prescription of proton pump inhibitor drugs.When mild steatorrhea, not accompanied by diarrhea and weight loss, appoint from 10 000 IU to 25 000 IU of lipase per reception. Mukovischidosis. The initial calculated dose for children under 4 years old is 1,000 IU of lipase per kilogram of body weight at each feeding, for children over 4 years old it is 500 U of lipase per pound of body weight at each meal. The dose should be selected individually, depending on the severity of the disease, the severity of steatorrhea and nutritional status. The maintenance dose for most patients should not exceed 10,000 IU of lipase per kilogram of body weight per day.
Side effects
Allergic reactions to the components of the drug. When using large doses of the drug are rarely observed: diarrhea, nausea, constipation, discomfort in the epigastric region.
Overdose
Data on drug overdose is not provided.
Interaction with other drugs
With simultaneous use with antacids containing calcium carbonate and / or magnesium hydroxide, it is possible to decrease the effectiveness of pancreatin. With simultaneous use, it is theoretically possible to reduce the clinical efficacy of acarbose.
special instructions
It is not recommended to use in the acute phase of chronic pancreatitis. In cystic fibrosis, the dose should be adequate to the amount of enzymes that are necessary for fat absorption, taking into account the quality and quantity of food consumed. lipase) due to an increased risk of stricture development (fibrous colonopathy) in the ileo-cecal and in the ascending colon. With a high activity of the lipase contained in pancreatin, the likelihood of nce of constipation in children. Increasing the dose of pancreatin in this category of patients should be carried out gradually. Violations of the digestive system can occur in patients with hypersensitivity to pancreatin, or in patients with meconium ileus or bowel resection in history.